)
SeaStar Medical Holding (ICU) investor relations material
SeaStar Medical Holding H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Key technology and clinical platform
QUELIMMUNE Selective Cytopheretic Device (SCD) targets immune-related renal injuries, with FDA approval for pediatric acute kidney injury (AKI) with sepsis under a humanitarian device exemption in 2024.
SCD is a platform technology with a consistent mechanism of action across multiple acute and chronic indications, including both pediatric and adult populations.
Adult indications are under breakthrough device designation, with six indications in the pipeline and a pivotal registration study underway for adult AKI.
The device modulates immune response by selectively binding and neutralizing activated neutrophils and monocytes, reducing cytokine storm without immunosuppression.
SCD is used in conjunction with continuous renal replacement therapy (CRRT), inducing apoptosis in targeted immune cells and returning them to the body to signal resolution of inflammation.
Market opportunity and commercialization
Pediatric AKI market in the U.S. is valued at $100 million with about 4,000 patients annually; adult AKI market is 50 times larger, with a $4.5 billion annual potential and over 200,000 patients.
QUELIMMUNE for children launched in July 2024, with initial adoption in eight U.S. pediatric hospitals and a focus on the top 50 children's hospitals.
Sales and distribution are managed directly, reducing middleman fees and improving hospital experience.
Health economics show reduced hospital stays and cost savings, with hospitals profiting from SCD use in pediatric AKI.
Strategy includes building a patient registry and deploying a specialized nursing team for smooth adoption.
Clinical results and ongoing studies
Pediatric clinical studies showed a survival rate increase to 77% and no dialysis dependency at 60 days, with no serious adverse events or infections.
Early SAVE registry data confirm a 75% survival rate in real-world pediatric use; further data to be presented in September.
Adult pivotal study (NEUTRALIZE-AKI) is 60% enrolled, targeting 200 patients, with a 90-day endpoint of all-cause mortality or dialysis dependency.
Interim analysis of the first 100 patients is expected in Q3, with final PMA submission planned for the second half of 2026.
Study sites include major academic, military, and community hospitals, with CMS reimbursement for trial participation.
Next SeaStar Medical Holding earnings date
Next SeaStar Medical Holding earnings date
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)